A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL-Reference-Cited by-同舟云学术

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Published:2018-04-19 Issue:16 Volume:131 Page:1805-1808
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sauter Craig S.¹²^ORCID,Matasar Matthew J.¹²,Schoder Heiko³,Devlin Sean M.⁴,Drullinsky Pamela¹²,Gerecitano John¹²,Kumar Anita¹²,Noy Ariela¹²,Palomba Maria L.¹²,Portlock Carol S.¹²,Straus David J.¹²,Zelenetz Andrew D.¹²,McCall Susan J.¹,Miller Shoshana T.¹,Courtien Amanda I.¹,Younes Anas¹²,Moskowitz Craig H.¹²

Affiliation:

1. Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY;

2. Department of Medicine, Weill Cornell Medical College, New York, NY; and

3. Molecular Imaging and Therapy Service, Department of Radiology, and

4. Department of Epidemiology and Biostatistics, MSKCC, New York, NY

Abstract

Key Points Ibrutinib plus R-ICE was safe, tolerable, and was not prohibitive to mobilizing hematopoietic stem cells for autologous transplantation. A favorable early signal in all evaluable rel/ref non-GC DLBCL achieving a complete metabolic remission was observed.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/16/1805/1467736/blood802561.pdf

Reference13 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med,1995

2. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12;Crump;J Clin Oncol,2014

3. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

4. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group;Barrington,2014

5. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma;Sauter;Blood,2015

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma;British Journal of Haematology;2024-09-12

2. SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

4. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies;Scientific Reports;2023-11-21

5. Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma;Blood Research;2023-11-15